96 Tests PN: B111398


45x Ab-conjugated beads (S4P10 - human IL-15 Ab-bead).PN: B111398A. One vial containing 100 µL of anti-human IL-15 conjugated to AimPlex Bead S4P10.

25x Biotin-detection Ab (human IL-15 Biotin-dAb).PN: B111398B. One vial containing 100 µL of biotinylated anti-human IL-15.

Lyophilized Standard Mix-Human Group 3 Panel B, 12-Plex. PN: HG3012B. One vial containing lyophilized recombinant human IL-9, IL-15, IL-16, IL-17C, IL-23p19, IL-24, IL-27, IL-31, IL-32, IL-34, OSM, and SCF.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human IL-15.  Can be multiplexed with other analytes in Human Group 3.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 3: Negligible

  • Sample volume: 15 µL/test


Interleukin 15 (Accession P40933) is expressed by many tissues and cell types such as monocytes, fibroblasts, myocyte, nerve cells, and dendritic cells. It has roles in maintaining homeostasis in both innate and adaptive immunity. IL-15 is a major growth factor responsible for NK maturation while also regulating their interactions with macrophages. This cytokine has two receptor subunits in common with that of IL-2’s, together they show the possibility of therapies for cancers and autoimmune diseases as well as implementation for the creation of new vaccines. Clinical trials are currently evaluating the safety and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma.


  1. A Phase I Study of Intravenous Recombinant Human IL-15 in Adults with Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer. National Institute of Health. www.clinicaltrials.gov

  2. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001; 97(1): 14-32. Doi: 10.1182/blood.V97.1.14.

  3. Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002; 13 (6): 429-39. PMID: 12401478.

  4. Waldmann TA. The biology of Interleukin-2 and Interleukin-15: Implications for cancer therapy and vaccine design. Nature Reviews Immunol. 2006; 6(8): 595-601. Doi: 10.1038/nri1901.